JAMA (IF=157) Cheng Ying and other teams from Jilin Provincial Cancer Hospital found effective immunotherapy for small cell lung cancer: domestic PD-1 fills the gap in the first-line treatment
Time of Update: 2022-10-20
On September 27, 2022, Cheng Ying's team at Jilin Provincial Cancer Hospital published an online publication in the Journal of the American Medical Association, one of the world's top four medical journals Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients with Extensive-Stage Small Cell Lung Cancer", which confirms that serplulimab () compared with chemotherapy alone Serplulimab) in combination with chemotherapy resulted in a significant improvement in overall survival (median overall survival of 15.
Pfizer's urgent domestic approval of Paxlovid is good for CDMO suppliers and domestic oral drugs
Time of Update: 2022-03-05
Junshi Biology announced on December 31 that the Ministry of Health of Uzbekistan has approved the emergency use authorization of its oral nucleoside anti-new coronavirus drug VV116, which shows that VV116 is effective and safe.
Learning from both China and the West, focusing on the gathering of big names in the "shi" world, focusing on the frontier progress of hematology and tumor, and promoting in-depth exchanges
Time of Update: 2022-01-26
In a phase Ib study of the safety of a novel T cell-binding bispecific antibody Glofitamab (hereinafter referred to as Glofit) combined with R-CHOP regimen for newly treated DLBCL, preliminary data showed that the overall response rate of 9 patients was as high as 100% , In terms of safety, the incidence of CRS in patients is extremely low, and there is no ICANS adverse event, and more samples are expected to be verified in the future .
BeiGene announces that Baiyueze(R) (Zebutinib) has been approved for the first time in Australia for the treatment of Fahrenheit's macroglobulinemia
Time of Update: 2021-10-09
This is the second approval recently obtained in the Asia-Pacific region following the approval of Baiyueze® in Singapore on October 1 for the treatment of mantle cell lymphomaThis approval is based o
Merck and BMS will be under pressure in the future
Time of Update: 2021-09-28
EP Vantage's latest analysis found that compared with 2019, almost all large pharmaceutical companies had improved their sales freshness index last year, with the exception of two companies-Amgen and Bristol-Myers Squibb (BMS) .
Lijin biology and methadone cooperate to evaluate the efficacy of keytruda combined with CD137 agonist
Time of Update: 2020-06-19
Transferred from: Medical Mission Hills recently, lyvgen announced a clinical trial cooperation agreement with MSD's subsidiaries to evaluate the efficacy of lvgn6051, the second generation 4
Analysis report on CDE drug review in March 2017 - drug intelligence registration and acceptance database
Time of Update: 2017-04-11
Highlights: in March, the number of new CDE contractors was 309, excluding reexamination (12), the same below In this month, CDE accepted 39 acceptance numbers of class 1 chemical drugs, involving 14
Review of three new blood tumor drugs approved by FDA in 2016
Time of Update: 2017-02-24
[industry trends of China Pharmaceutical network] common hematological tumors mainly include all kinds of leukemia, multiple myeloma and malignant lymphoma Statistics from western countries show that